Breast cancer cells were treated with Bay-11-7082 at various concentrations for 24, 48 or 72 hrs to determine which concentration and duration of treatment have the greatest effect on inhibiting NF-κB activation. The gene discussed is NFKB1; the disease is breast carcinoma.